HOPA 2018 | Treating GvHD: current challenges and newly approved drugs
Katie Gatwood
Graft versus host disease (GvHD) remains to be one of the leading causes of morbidity and mortality in patients who have undergone bone marrow transplant. Here, Katie Gatwood, PharmD, BCOP, of Vanderbilt University Medical Center, Nashville, TN, briefly discusses the challenges with current treatment options for GvHD and gives an update on newly approved drugs that can be used to effectively treat patients. This interview was recorded at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.
Related videos
1:06
The role of nurses in apheresis during CAR T-cell therapy
Erik Aerts
1:24
Educational material for HCPs on CAR T-cell therapy
Erik Aertes
1:58
Educating and training nurses involved with CAR T-cell therapy
Diana Comerford
0:47
Patient monitoring following CAR T-cell therapy
Erik Aerts
2:20
CAR-T assessment in the ambulatory care setting
Diana Comerford
